The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Avacta rafioligand partner is on same science park as novartis.....
The Avacta chemo market potential is very big and could dwarf other acquisitions. I'm looking at phase 1 results as the window of opportunity is small.
Great thoughts ben4
Hopefully there might be some truth in some of that. It's just the gist of the article was that they were trying to tie hospitals up with equipment and a sticky process
The fact that they see it as an important target market is positive
Yes, that's a fair assessment Sang - though I thought it interesting as:
a) they clearly see Radioligand's as the future, and we're part of that
b) If Novartis are buying up tech in that space, it's not unforeseeable that they might just buy up POINT - market cap only $791m and Novartis have a big war chest
c) Activating the radioligand in the tumour with FAP may be a superior technology to Novartis's targeting system
d) If Novartis are stealing a march on everyone else through acquisitions, presumably that would make us/POINT more attractive to competitors
I believe we will have Avacta featuring more in the press and be seen working with the government.Today’s press on how efficient an efficient and reliable LFT would work at schools and universities and at corporate businesses( once OTC approved, which I suspect is any day ) and with overseas interest really kicking in, the monthly demand will easily exceed current max est of 60 mill a month and we could see new SOP etc.
US est for Test demand globally is 2- 2 1/2 bill !!!
Friday is always interesting, but with the Week end coming up, one would expect more news flow with regards to the use of Rapid daily antigen LFT and one that can identify the Delta Variant as well.
BUY AVACTA on a Friday and you seldom go wrong.
Reads the CEO post result Q&A and you will see how much he wants Radiotherapy and will and have paid for it !!!
Yeah but 4xben.I was looking at that the other day and they are very much a competitor to Point and they seem to be ahead although it's possible that Point have a superior offering.
I saw it as a potential threat to Point.
People kept posting about Novartis so did a quick Google News search and found this quite interesting - looks like they're on a little acquisition spree in the space, within which we have a deal with POINT Biopharma. May not be relevant at all but food for thought!
"Novartis is hoping to cement an early lead in a potential $10bn market for a new type of cancer treatment, called novel radioligand therapy, after positive results from its trials.
Vas Narasimhan, Novartis’s chief executive, said the pharmaceutical company has large-scale manufacturing capacity and relationships with hospitals, which will have to invest to adapt to deliver the treatments, that would lead to a “virtuous cycle” where competitors find it harder to displace the company’s dominance.
“We believe it could be, in the coming decade, a $10bn plus market,” he told the Financial Times. “When you look at the cancers it could address, you certainly have the opportunity to go much, much larger.”
Originally developed by physicists from CERN, the European organisation for nuclear research, Novartis’s radioligand therapy delivers beta radiation to tumours through an infusion, which is more targeted than the blunt tool of radiotherapy.
The technologies were acquired in two deals in 2018, with Novartis buying Endocyte for $2.1bn, and Advanced Accelerator Applications, founded by the CERN scientists, for $3.9bn."
(Copy/paste the article headline into google, click the first link, to get around the paywall)
https://www.ft.com/content/94b71fcc-8a58-4fcb-b5e1-cfae4b259b17